Molecular Epidemiology of Invasive Group B Streptococcus in South Africa, 2019–2020 - Takeaways - MDSpire

Molecular Epidemiology of Invasive Group B Streptococcus in South Africa, 2019–2020

  • By

  • Buhle Ntozini

  • Sibongile Walaza

  • Benjamin Metcalf

  • Scott Hazelhurst

  • Linda de Gouveia

  • Susan Meiring

  • Dineo Mogale

  • Senzo Mtshali

  • Arshad Ismail

  • Kedibone Ndlangisa

  • Mignon Du Plessis

  • Vanessa Quan

  • Sopio Chochua

  • Lesley McGee

  • Anne von Gottberg

  • Nicole Wolter

  • December 31, 2024

  • 0 min

Share

  • 1

    Group B Streptococcus (GBS) is a major cause of neonatal meningitis and sepsis, as well as disease in adults.

  • 2

    A total of 1748 invasive GBS cases were reported in South Africa from 2019 to 2020, with 661 isolates characterized.

  • 3

    The predominant GBS serotypes identified were III (42.8%), Ia (27.9%), and V (11.9%), with five clonal complexes observed.

  • 4

    Antimicrobial resistance was noted, with 91.5% of isolates resistant to tetracycline and reduced susceptibility to penicillin in one isolate.

  • 5

    Current vaccine developments target the predominant GBS serotypes, aiming to improve coverage and combat rising antibiotic resistance.

Original Source(s)

Molecular Epidemiology of Invasive Group B Streptococcus in South Africa, 2019–2020

  • by Buhle Ntozini, Sibongile Walaza, Benjamin Metcalf, Scott Hazelhurst, Linda de Gouveia, Susan Meiring, Dineo Mogale, Senzo Mtshali, Arshad Ismail, Kedibone Ndlangisa, Mignon Du Plessis, Vanessa Quan, Sopio Chochua, Lesley McGee, Anne von Gottberg, Nicole Wolter

  • December 31, 2024

Related Content

Adjunctive acupuncture for sepsis-associated acute gastrointestinal injury: a systematic review, meta-analysis, and exploratory Bayesian network meta-analysis

The Prognostic Value of Red Cell Distribution Width-to-Albumin Ratio for 28-Day Mortality in Sepsis Patients: A Multicenter Analysis Based on the eICU Collaborative Research Database

Integrated multi-omics deciphers sepsis immune dysregulation: a dual-pathway targeted small-molecule therapy improves survival and ameliorates multi-organ dysfunction